Abstract: Multiple myeloma (MM) is a hematologic malignancy of clonal proliferation of plasma cells, which ranks the second in hematologic malignancy. Proteasome is a complex enzyme in the cell, which can degrade ubiquitin-labeled proteins and regulate intracellular protein levels and play an important role in maintaining the stability of the intracellular environment. In recent years, with the application of new proteasome inhibitors, great progress has been achieved in MM treatment, further improving the therapeutic efficacy of myeloma.